NYSE · Common Stock · Pharmaceutical Preparations
multinational biopharmaceutical company headquartered in Gaithersburg, Maryland, USA
18 entities across 8 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-27 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Professional LLC | Delaware | |
| Cangene bioPharma LLC | Maryland | |
| Emergent Commercial Operations Frederick Inc. | Maryland | |
| Emergent Biodefense Operations Lansing LLC | Delaware | |
| Emergent Devices Inc. | Delaware | |
| Emergent Europe Inc. | Delaware | |
| Emergent International Inc. | Delaware | |
| Emergent Manufacturing Operations Baltimore LLC | Delaware | |
| Emergent Product Development Gaithersburg Inc. | Delaware | |
| Emergent Travel Health Inc. | Delaware | |
| Emergent Acquisition Unlimited Company | Ireland | |
| Emergent BioSolutions Ireland Limited | Ireland | |
| Emergent Netherlands B.V. | Netherlands | |
| Emergent Operations Ireland Limited | Ireland | |
| Emergent Sales and Marketing Australia Pty Ltd. | Australia | |
| Emergent Sales and Marketing Germany GmbH | Germany | |
| Emergent Sales and Marketing Singapore Pte. Ltd. | Singapore | |
| Emergent BioSolutions UK Ltd. | England and Wales |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $1.6B | $305.1M | $395.0M | 58.1% | 53,800,000 |
| FY2021 | $1.8B | $230.9M | $96.1M | 50.3% | 54,100,000 |
| FY2022 | $1.1B | −$223.8M | −$149.9M | 34.4% | 50,100,000 |
| FY2023 | $1.0B | −$760.5M | −$257.9M | 30.3% | 51,200,000 |
| FY2024 | $1.0B | −$190.6M | $35.8M | — | 53,000,000 |
| FY2025 | $742.9M | $52.6M | $156.8M | — | 56,700,000 |
12 institutions tracked — 10 added, 2 reduced. Index money added 519,008 shares while active managers cut 124,477.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| BlackRock, Inc. | Index | 4,716,599 | +375,137 | $39.5M |
| MORGAN STANLEY | Active fund | 469,715 | −274,821 | $3.9M |
| STATE STREET CORP | Index | 2,929,238 | +79,537 | $24.6M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 1,337,243 | +64,334 | $11.2M |
| FMR LLC | Active fund | 214,169 | +60,281 | $1.8M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 1,041,151 | +51,474 | $8.7M |
| CITADEL ADVISORS LLC | Hedge fund | 162,000 | +33,800 | $1.4M |
| BANK OF AMERICA CORP /DE/ | Active fund | 152,219 | −31,224 | $1.3M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 683,247 | +27,200 | $5.7M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 47,548 | +5,161 | $399,000 |
| JPMORGAN CHASE & CO | Active fund | 24,473 | +2,932 | $207,042 |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 151,966 | +720 | $1.3M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Emergent BioSolutions Inc. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
